{"preliminary_commentary":{"by_channel":{"x_thread":16,"youtube":5,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04620239\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"UCM301","nct_id":"NCT04620239","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ucm301-nct04620239. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"UCM301","arms":[{"description":"Induction Treatment phase:1-3 padeliporfin VTP treatments provided 4 weeks (28 +/-3 days) apart.\n\nMaintenance Treatment Phase: Repeated maintenance VTP treatments during this period will be provided for patients who show evidence of tumor recurrence that is deemed treatable.","label":"padeliporfin VTP","type":"EXPERIMENTAL"}],"collaborators":["PrimeVigilance","ICON plc"],"completion_date":{"date":"2028-08-01","type":"ESTIMATED"},"conditions":["Transitional Cell Cancer of Renal Pelvis and Ureter"],"enrollment":{"count":89,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"padeliporfin VTP","otherNames":["WST11"],"type":"DRUG"}],"last_update":"2026-07-30","lead_sponsor":"Steba Biotech S.A.","official_title":"Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of patients with absence of UTUC tumors in the entire ipsilateral calyces, renal pelvis and ureter","timeFrame":"28 +/- 3 days post last treatment"}],"references":[],"start_date":{"date":"2021-03-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study","url":"https://clinicaltrials.gov/study/NCT04620239"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ucm301-nct04620239"}